Pentosan Polysulfate Sodium (PPS)

The Most Underrated Joint Compound

Pentosan Polysulfate Sodium (PPS) is almost entirely unknown in mainstream supplement communities despite having one of the strongest evidence bases for cartilage protection of any injectable compound available. Its obscurity is largely a function of its origins: it has been used in veterinary orthopaedics (as Cartrophen Vet) for over 30 years, with an extensive clinical database from equine and canine joint disease studies that has only recently been extrapolated to human use.

Mechanism of Action

PPS is a semi-synthetic analogue of heparin sulphate - one of the primary glycosaminoglycans (GAGs) that constitute articular cartilage's extracellular matrix. Articular cartilage has no blood supply and extremely limited self-repair capacity. GAG depletion in the cartilage matrix is the primary event in osteoarthritic deterioration.

Chondroprotection: PPS directly replenishes depleted GAGs in cartilage, restoring the water-binding capacity and compressive resilience that characterise healthy articular cartilage.

Synovial fluid normalisation: Intra-articular injection of PPS improves synovial fluid viscosity and reduces inflammatory mediators (prostaglandins, matrix metalloproteinases) that drive cartilage degradation.

Growth factor stimulation: PPS binds and concentrates fibroblast growth factor (FGF) at the cartilage surface, amplifying chondrocyte proliferation signals.

Anti-inflammatory: PPS has significant anti-inflammatory properties through inhibition of complement activation and cytokine suppression - particularly relevant for the chronic low-grade inflammation that perpetuates joint disease.

Human Clinical Data

A 2018 systematic review of 11 clinical trials in human osteoarthritis found significant improvements in pain scores and functional measures with injectable PPS versus placebo. A 2020 randomised controlled trial demonstrated cartilage volume preservation (measured by MRI) in knee osteoarthritis patients receiving PPS injections versus placebo controls - a structural endpoint rarely achieved by any intervention.

The Anticoagulant Risk

PPS has measurable anticoagulant activity, though significantly less than heparin. At therapeutic doses for joint repair, the clinical significance is low in healthy individuals. However, this property means PPS must not be combined with anticoagulant medications, and should be discontinued at least 2 weeks before elective surgery. Regular monitoring of platelet count is advisable with extended use protocols.